Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000358104 | SCV000339651 | uncertain significance | not provided | 2016-02-24 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004021197 | SCV005022237 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-01-02 | criteria provided, single submitter | clinical testing | The c.1992C>T variant (also known as p.G664G), located in coding exon 7 of the BLM gene, results from a C to T substitution at nucleotide position 1992. This nucleotide substitution does not change the glycine at codon 664. This nucleotide position is not well conserved in available vertebrate species. In silico splice site analysis predicts that this alteration may result in the creation or strengthening of a novel splice acceptor site. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |